Did you know there’s a good chance you already have patients using peptide-based therapies?
Ozempic made the category famous, but semaglutide is only one small piece of a much bigger healthcare shift. Peptides are showing up in conversations around weight management, metabolic health, inflammation, recovery, body composition, longevity, hormone optimization, and regenerative medicine. For dental hygienists, the patient sitting in our chair is evolving faster than many of our medical history forms can keep up with.
That’s one reason I developed my newest course, “Beyond Ozempic: The Role of Peptides in Oral Health, Airway, and Whole-Body Care.” Before we can understand what peptides might mean for dentistry, however, we need a Peptides 101.
First: What Exactly Is a Peptide?
At the simplest level, peptides are short chains of amino acids. Many occur naturally in the human body and function as signaling molecules, essentially helping cells communicate and influencing processes such as appetite, metabolism, hormone release, inflammation, immune response, and tissue repair.
Medicine has learned to create or modify some of these molecules for therapeutic purposes. GLP-1 receptor agonists are the most familiar examples. Semaglutide, the active ingredient in Ozempic and Wegovy, mimics the activity of the naturally occurring GLP-1 hormone. Tirzepatide, sold as Mounjaro and Zepbound, acts on both GIP and GLP-1 receptors.
Recognizing that difference is essential because “peptide” is a broad category. It does not automatically mean a therapy is FDA approved, proven effective, or even legally marketed for human use.
10 Peptide Names You’re Likely to Hear
Hygienists don’t need to memorize peptide pharmacology, but these are names worth recognizing:
- Semaglutide – GLP-1 therapy used for diabetes and weight management.
- Tirzepatide – dual GIP/GLP-1 therapy for diabetes and weight management.
- Liraglutide – another GLP-1 receptor agonist.
- Retatrutide – an investigational triple-agonist gaining significant attention but not FDA approved.
- Tesamorelin – an FDA-approved growth hormone-releasing factor analog for a specific indication in patients with HIV; used for its off-label use of decreasing fat around the abdomen
- BPC-157 – promoted for injury recovery and healing but not FDA approved.
- CJC-1295 – marketed in the wellness space to influence growth hormone pathways; not FDA approved.
- Ipamorelin – another growth hormone secretagogue commonly promoted by peptide and wellness clinics; not FDA approved.
- GHK-Cu – a copper-binding peptide increasingly discussed in skin, hair, and regenerative applications.
- Thymosin alpha-1 – an immune-modulating peptide available in some countries but not FDA approved in the United States.
Why This Belongs in Dental Hygiene
We’re trained to evaluate much more than teeth. Today, hygienists may examine and engage patients in person, through virtual care, or through remote monitoring, giving us multiple opportunities to notice changes over time.
We assess inflammation. We evaluate saliva and tissues. We review medications, sleep, nutrition, tobacco use, diabetes, cardiovascular risk, and airway health. Peptide therapies add another layer to that story.
Recent literature is already exploring the oral implications of GLP-1 therapies. Reported and potential issues include xerostomia, altered taste, halitosis, reflux, vomiting-related erosion, nutritional changes, changes associated with reduced fluid and food intake, and changes associated with rapid weight loss and other body changes. Researchers are also investigating whether GLP-1 therapies could influence periodontal inflammation and alveolar bone biology, although much of that evidence remains preliminary.¹˒²
There are procedural considerations, too. Current semaglutide labeling notes delayed gastric emptying and reports of pulmonary aspiration in patients undergoing procedures requiring general anesthesia or deep sedation.³
The point isn’t for hygienists to recommend peptide therapies. It’s for us to recognize them, document them, understand possible implications, and know when something requires a conversation with the dentist or the patient’s medical provider.
The Wild West Problem
Perhaps the most important part of Peptides 101 is understanding where the peptide came from. A patient may receive an FDA-approved prescription. Another may receive a compounded medication through a legitimate medical provider. Someone else may order a vial online labeled “for research use only” and inject it after following instructions found on social media.
In 2026, the FDA has become increasingly aggressive about this gray market. The agency has issued warning letters to companies selling injectable peptides labeled “research use only” or “not for human consumption” when evidence showed they were actually being marketed for human use. The FDA specifically warns that these products may have unknown quality and may be harmful.⁴
The regulatory environment around compounded GLP-1 medications is changing as well. With the semaglutide and tirzepatide shortages resolved, the broad shortage-related pathway that allowed copies of these drugs to be compounded has narrowed substantially. In April 2026, the FDA also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list after concluding there was not sufficient clinical need for outsourcing facilities to compound them from bulk substances.⁵
Other peptides are under scrutiny. FDA documents identify significant questions surrounding the characterization, purity, aggregation, immunogenicity, and clinical evidence for compounds such as BPC-157 and ipamorelin. FDA also plans additional consideration of noninjectable GHK-Cu through its Pharmacy Compounding Advisory Committee before the end of February 2027.⁶˒⁷
That makes one additional health history question increasingly useful: “Where are you getting it?”
AI Will Help Us Ask Better Questions
The traditional medical history is also due for an upgrade.
We’re rapidly approaching a world where patients will complete intelligent, AI-supported health histories before ever arriving at the practice. Instead of simply capturing a list of medications and conditions, these systems will be able to identify missing information, recognize patterns, and flag areas requiring clarification.
Generative AI is already pushing us in that direction, helping to support and aid clinical decision-making. Dental-specific clinical chat platforms such as Trust AI’s Isaac now provide clinical decision support around medications, contraindications, treatment considerations, and complex medical-dental questions.⁸ These tools can help a clinician investigate an unfamiliar peptide, potential adverse effects, drug interactions, supplement considerations, or new guidance far faster than manually searching dozens of resources.
This connects to what I believe are three of the biggest forces shaping the future of dentistry: pattern, predictability, and precision prevention.
Our ability to collect more complete health information, recognize patterns earlier, and connect oral findings with systemic changes will ultimately allow us to personalize preventive care in ways we simply couldn’t before. Peptides are just one example of why that future is arriving so quickly.
As hygienists, we don’t need to become peptide prescribers. However, we do need to understand the language, recognize the therapies showing up in our operatories, ask better questions, and stay curious about what the science says next.
Over the next twelve months, I’ll be diving deeper into peptides to help you stay current and in-the-know with the latest changes. For teams, study clubs, and organizations interested in exploring the topic further, or for clinicians who simply want to stay informed as the evidence and regulations evolve, please contact me or visit MelissaKTurner.com.
References
- Kofman K, Ouanounou A. Oral health considerations and dental management guidelines for semaglutide medications. Can J Diabetes. Published online April 10, 2026. doi:10.1016/j.jcjd.2026.03.008.
- Nijakowski K, Gruszczyński D, Łacinik S, et al. Relationship between GLP-1-based therapies and periodontal health: a systematic review of current evidence and future perspectives. Int J Mol Sci. 2026;27(14):6447. doi:10.3390/ijms27146447.
- US Food and Drug Administration. Ozempic/semaglutide prescribing information. Updated 2026.
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated 2026.
- US Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Published April 30, 2026.
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: BPC-157-related bulk drug substances. 2025.
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
- Trust AI. Isaac Clinical Chat: Clinical Intelligence for Dentistry. Accessed August 10, 2026.
About the author
Melissa K. Turner is a dental industry brand strategist, healthcare innovation advisor, and clinical thought leader specializing in saliva, the oral microbiome, and clinical technology. She designs influence systems that shape how innovation earns trust and adoption across dentistry and healthcare. Turner is the co-founder of The Denobi Awards and the National Mobile & Teledentistry Conference, and the creator of the HALO System™ (Human + AI Leadership Optimization). Her work bridges clinical insight, brand strategy, and emerging technology to help organizations and leaders build credibility in an AI-driven world. To become XPERT Certified or receive your free downloadable xerostomia protocol, contact hello@melissakturner.com. Click here to subscribe to Melissa’s new weekly LinkedIn newsletter, The Future of Dentistry Report.
Figures and Images
